{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:37:04Z","timestamp":1780321024227,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Red de Grupos de Estudio de la Diabetes en Atenci\u00f3n Primaria de la Salud \u2013 RedGDPS"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Prim. Care"],"DOI":"10.1186\/s12875-025-03117-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T03:45:10Z","timestamp":1763955910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chronic kidney disease screening in primary care: a descriptive analysis of the Girona Sud health region"],"prefix":"10.1186","volume":"26","author":[{"given":"Joan","family":"Barrot-de la Puente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lopez Arp\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Ramon Granes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Escrib\u00e0 Planes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berta","family":"Fernandez-Camins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan","family":"Vlacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Franch-Nadal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"3117_CR1","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1186\/s12889-024-21065-9","volume":"24","author":"K Qin","year":"2024","unstructured":"Qin K, Qing J, Wang Q, et al. Epidemiological shifts in chronic kidney disease: a 30-year global and regional assessment. BMC Public Health. 2024;24:3519.","journal-title":"BMC Public Health."},{"key":"3117_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20:473\u201385.","journal-title":"Nat Rev Nephrol."},{"key":"3117_CR3","doi-asserted-by":"crossref","unstructured":"Borg R, Kriegbaum M, Andersen CL, Persson F. #2976 Chronic kidney disease with comorbidity in primary care: cardiorenal treatment, quality of care and prognosis. Nephrol Dial Transplant. 2023;38(Suppl 1):gfad063c_2976.","DOI":"10.1093\/ndt\/gfad063c_2976"},{"issue":"3","key":"3117_CR4","doi-asserted-by":"publisher","first-page":"678","DOI":"10.3390\/jcm13030678","volume":"13","author":"F Mallamaci","year":"2024","unstructured":"Mallamaci F, Tripepi G. Risk factors of chronic kidney disease progression: between old and new concepts. J Clin Med. 2024;13(3):678.","journal-title":"J Clin Med."},{"key":"3117_CR5","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. 2024. Available from: https:\/\/kdigo.org\/wp-content\/uploads\/2024\/03\/KDIGO-2024-CKD-Guideline.pdf.\u00a0Cited 2025 Mar 19."},{"key":"3117_CR6","doi-asserted-by":"crossref","unstructured":"Montero N, Oliveras L, Mart\u00ednez-Castelao A, et al.; GEENDIAB. Clinical practice guideline for detection and management of diabetic kidney disease: a consensus report by the Spanish Society of Nephrology. Nefrologia. 2025;45(Suppl 1):1\u201326.","DOI":"10.1016\/j.nefroe.2025.04.005"},{"key":"3117_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12875-023-02077-7","volume":"24","author":"R Borg","year":"2023","unstructured":"Borg R, Kriegbaum M, Grand MK, et al. Chronic kidney disease in primary care: risk of cardiovascular events, end stage kidney disease and death. BMC Prim Care. 2023;24:128.","journal-title":"BMC Prim Care."},{"key":"3117_CR8","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Maset R, Bover J, Segura de la Morena J, et al. Documento de informaci\u00f3n y consenso para la detecci\u00f3n y manejo de la enfermedad renal cr\u00f3nica. Nefrologia. 2022;42(3):233\u201364.","DOI":"10.1016\/j.nefro.2021.07.010"},{"key":"3117_CR9","unstructured":"Vaidya SR, Aeddula NR. Chronic kidney disease. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535404\/.\u00a0Updated 2024 Jul 31; cited 2025 Jan 1."},{"issue":"12","key":"3117_CR10","doi-asserted-by":"publisher","first-page":"e064723","DOI":"10.1136\/bmjopen-2022-064723","volume":"12","author":"M Stedman","year":"2022","unstructured":"Stedman M, Heald A, Robinson A, et al. Associations and mitigations: an analysis of the changing risk factor landscape for chronic kidney disease in primary care using national general practice level data. BMJ Open. 2022;12(12):e064723.","journal-title":"BMJ Open."},{"key":"3117_CR11","doi-asserted-by":"crossref","unstructured":"Alfego D, Ennis J, Gillespie B, et al. Chronic kidney disease testing among at-risk adults in the U.S. remains low: real-world evidence from a national laboratory database. Diabetes Care. 2021;44(9):2025\u201332.","DOI":"10.2337\/dc21-0723"},{"key":"3117_CR12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.pcd.2024.06.006","volume":"18","author":"MA S\u00e1nchez-Calavera","year":"2024","unstructured":"S\u00e1nchez-Calavera MA, Navarro RG, Otal EA, et al. Prevalence and characteristics of chronic kidney disease in people with type 2 diabetes mellitus in the Autonomous Community of Aragon. Prim Care Diabetes. 2024;18:555\u201360.","journal-title":"Prim Care Diabetes."},{"key":"3117_CR13","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.pcd.2021.02.003","volume":"15","author":"M Mata-Cases","year":"2021","unstructured":"Mata-Cases M, Franch-Nadal J, Real J, et al. Evaluation of clinical and antidiabetic treatment characteristics of different sub-groups of patients with type 2 diabetes: data from a Mediterranean population database. Prim Care Diabetes. 2021;15:588\u201395.","journal-title":"Prim Care Diabetes."},{"issue":"5","key":"3117_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.endinu.2017.03.003","volume":"64","author":"J Franch-Nadal","year":"2017","unstructured":"Franch-Nadal J, Mediavilla-Bravo J, Mata-Cases M, et al. Prevalence and control of type 2 diabetes mellitus among primary care physicians in Spain: PRISMA study. Endocrinol Diabetes Nutr. 2017;64(5):265\u201371.","journal-title":"Endocrinol Diabetes Nutr."},{"key":"3117_CR15","doi-asserted-by":"crossref","unstructured":"Banegas JR, S\u00e1nchez-Mart\u00ednez M, Gij\u00f3n-Conde T, et al. Numerical values and impact of hypertension in Spain. Rev Esp Cardiol (Engl Ed). 2024;In press.","DOI":"10.1016\/j.rec.2024.03.011"},{"issue":"9","key":"3117_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1157\/13092314","volume":"127","author":"O Vegazo","year":"2006","unstructured":"Vegazo O, Banegas JR, Civeira F, et al. Prevalencia de dislipemia en las consultas ambulatorias del Sistema Nacional de Salud: Estudio HISPALIPID. Med Clin (Barc). 2006;127(9):331\u20134.","journal-title":"Med Clin (Barc)."},{"issue":"10","key":"3117_CR17","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.recesp.2023.12.019","volume":"77","author":"L Feijoo","year":"2024","unstructured":"Feijoo L, Rey-Brandariz J, Guerra-Tort C, et al. Prevalence of obesity in Spain and its autonomous communities, 1987\u20132020. Rev Esp Cardiol (Engl Ed). 2024;77(10):809\u201318.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"1","key":"3117_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ckj\/sfac206","volume":"16","author":"C Santos-Ara\u00fajo","year":"2022","unstructured":"Santos-Ara\u00fajo C, Mendon\u00e7a L, Carvalho DS, et al. Twenty years of real-world data to estimate chronic kidney disease prevalence and staging in an unselected population. Clin Kidney J. 2022;16(1):111\u201324.","journal-title":"Clin Kidney J."},{"key":"3117_CR19","doi-asserted-by":"crossref","unstructured":"Ortega E, Genua I, Mata-Cases M, et al. First manifestation of cardiovascular disease according to age and sex in a Mediterranean country. Front Cardiovasc Med. 2024;11:1403363.","DOI":"10.3389\/fcvm.2024.1403363"},{"issue":"4","key":"3117_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.aprim.2014.06.003","volume":"47","author":"B Salvador Gonz\u00e1lez","year":"2015","unstructured":"Salvador Gonz\u00e1lez B, Rodr\u00edguez Pascual M, Ruip\u00e9rez Guijarro L, et al. Enfermedad renal cr\u00f3nica en Atenci\u00f3n Primaria: prevalencia y factores de riesgo asociados. Aten Primaria. 2015;47(4):236\u201345.","journal-title":"Aten Primaria."},{"key":"3117_CR21","doi-asserted-by":"publisher","first-page":"1101068","DOI":"10.3389\/fphar.2023.1101068","volume":"14","author":"S Alshahrani","year":"2023","unstructured":"Alshahrani S. Renin-angiotensin-aldosterone pathway modulators in chronic kidney disease: a comparative review. Front Pharmacol. 2023;14:1101068.","journal-title":"Front Pharmacol."},{"key":"3117_CR22","doi-asserted-by":"publisher","first-page":"1213473","DOI":"10.3389\/fimmu.2023.1213473","volume":"14","author":"ZC Dai","year":"2023","unstructured":"Dai ZC, Chen JX, Zou R, et al. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease. Front Immunol. 2023;14:1213473.","journal-title":"Front Immunol."},{"issue":"9","key":"3117_CR23","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.2337\/dc20-2715","volume":"44","author":"N Stempniewicz","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, et al. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care. 2021;44(9):2000\u20139.","journal-title":"Diabetes Care."},{"key":"3117_CR24","doi-asserted-by":"crossref","unstructured":"Birn H, Nelveg-Kristensen KE, Frederiksen LE, et al. The management of chronic kidney disease in primary care in Denmark: patient characteristics, treatment, follow-up, progression and referral. Clin Kidney J. 2025;18(2):sfae393.","DOI":"10.1093\/ckj\/sfae393"},{"key":"3117_CR25","unstructured":"Institut Catal\u00e0 de la Salut (ICS). Guia de pr\u00e0ctica cl\u00ednica sobre la diabetis mellitus tipus 2. 2015. Available from: https:\/\/ics.gencat.cat\/web\/.content\/Documents\/assistencia\/gpc\/GuiaDiabetis2015.pdf.\u00a0Cited 2025 Mar 19."}],"container-title":["BMC Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12875-025-03117-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12875-025-03117-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T22:52:53Z","timestamp":1767048773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12875-025-03117-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3117"],"URL":"https:\/\/doi.org\/10.1186\/s12875-025-03117-0","relation":{},"ISSN":["2731-4553"],"issn-type":[{"value":"2731-4553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"2 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsink,1 October 2024. The IDIAP Jordi Gol Ethics Committee approved the study, protocol approval number 23\/030-P, on 29\/03\/2023. The need for informed consent was waived by the Clinical Research Ethics Committee of IDIAP Jordi Gol, as the study involved retrospective analysis of anonymized data. This waiver complies with the national regulations outlined in the Biomedical Research Law 14\/2007 (Spain), which allows the use of health data for research purposes without informed consent when data are anonymized and obtaining consent is impracticable.Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J. B-P has received speaking fees from Boehringer Ingelheim. Astra-Zeneca.Lilly. MSD. Novo Nordisk. Sanofi. J. F-N has received advisory and or speaking fees from Astra-Zeneca. Ascensia, Boehringer Ingelheim, GSK, Lilly, MSD, Novartis, Novo Nordisk and Sanofi; he has received research grants to the institution from Astra-Zeneca, GSK, Lilly, MSD, Novartis, Novo Nordisk, Sanofi and Boehringer Ingelheim. M. R-G; B.F-C; M.E-P; B.V and J.L-A declare no conflict of interest for this analysis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"409"}}